Treatment‐Line‐Specific Outcomes of Obinutuzumab in Membranous Nephropathy: A Systematic Review and Meta‐Analysis
International Journal of Nephrology · 2026-01 · 2026 (1)
DOI: 10.1155/ijne/6372570 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Nephrology, online erschienen am 09.11.2026. Verfasst von Abdelrahman M Elettreby und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine Mansoura University Mansoura Egypt mans.edu.eg. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Primary membranous nephropathy (PMN) is an autoimmune glomerulonephritis triggered by B‐cell dysfunction, where rituximab achieved clinical remission in about 55%–65% of patients, while 35%–45% of patients are nonresponders. Obinutuzumab, a humanized type II anti‐CD20 monoclonal antibody that showed more profound B‐cell depletion, may improve treatment outcomes in both treatment‐naïve and refractory patients. This systematic review and meta‐analysis evaluate the clinical and immunological outcomes of obinutuzumab in PMN.
Methods
We performed a systematic literature search across PubMed, Scopus, and Web of Science through January 2026 to identify studies assessing the effect of obinutuzumab in PMN. We performed meta‐analyses using the meta package in R software.
Results
As first‐line therapy, pooled complete response was 0.324, rising from 0.257 at 6 months to 0.485 at 12 months, and partial response was 0.508. Clinical remission and immunological response were both high ranging between 81% and 89%. As second‐line therapy after rituximab, complete response was lower (18.1%) but partial response remained high (54.7%), with clinical remission increasing to 83.5% at 12 months and immunological response improving significantly to 90.5% at 12 months. In rituximab‐refractory patients, complete and partial response rates were 27.8% and 54.3%, respectively, with clinical remission improving notably by 12 months (84.5%). Secondary analyses showed increased serum albumin and reduced proteinuria over time.
Conclusion
Obinutuzumab was associated with clinical and immunological remission in PMN. Clinical and immunological responses were observed across treatment‐naïve, previously treated, and rituximab‐refractory populations, though differences between these nonrandomized treatment‐line groups should not be interpreted as comparative efficacy. No clear short‐term change in kidney‐function measures was detected.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine Mansoura University Mansoura Egypt mans.edu.eg.
- Department of Medicine King Faisal Specialist Hospital and Research Centre Riyadh Saudi Arabia kfshrc.edu.sa.
- Department of Statistics Comilla University Cumilla 3506 Bangladesh cou.ac.bd.
- Faculty of Medicine An-Najah National University Nablus State of Palestine najah.edu.
- Department of Child Health College of Medicine King Khalid University Abha Saudi Arabia kku.edu.sa.
- Department of Pharmacology College of Medicine Imam Mohammad Ibn Saud Islamic University (IMSIU) Riyadh 13317 Saudi Arabia imamu.edu.sa.
ORCID-Profile: Abdelrahman M Elettreby, Ahmed A Abo Elnaga, Faisal A Al-Harbi, Sayed Sayem, Tamara Aburiash, Alam Eldin Musa Mustafa, Dina Khodeer, Ahmed Mohamed Aboelkheir, Mostafa Gamal
Zitieren
APA
Elettreby, A. M., Elnaga, A. A. A., Al-Harbi, F. A., Sayem, S., Aburiash, T., Mustafa, A. E. M., Khodeer, D., Aboelkheir, A. M., & Gamal, M. (2026). Treatment‐Line‐Specific Outcomes of Obinutuzumab in Membranous Nephropathy: A Systematic Review and Meta‐Analysis. International Journal of Nephrology, 2026(1). https://doi.org/10.1155/ijne/6372570
Vancouver
Elettreby AM, Elnaga AAA, Al-Harbi FA, Sayem S, Aburiash T, Mustafa AEM, et al. Treatment‐Line‐Specific Outcomes of Obinutuzumab in Membranous Nephropathy: A Systematic Review and Meta‐Analysis. International Journal of Nephrology. 2026;2026(1). doi:10.1155/ijne/6372570
BibTeX
@article{Elettreby2026,
author = {Elettreby, Abdelrahman M and Elnaga, Ahmed A Abo and Al-Harbi, Faisal A and Sayem, Sayed and Aburiash, Tamara and Mustafa, Alam Eldin Musa and Khodeer, Dina and Aboelkheir, Ahmed Mohamed and Gamal, Mostafa},
title = {Treatment‐Line‐Specific Outcomes of Obinutuzumab in Membranous Nephropathy: A Systematic Review and Meta‐Analysis},
journal = {International Journal of Nephrology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ijne/6372570}
}
EUVIMED